Literature DB >> 10762141

Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine.

A M Lozano1, A E Lang, R Levy, W Hutchison, J Dostrovsky.   

Abstract

Dopaminergic agents reverse parkinsonism but commonly induce dyskinesia in patients with Parkinson's disease (PD) on long-term levodopa therapy. The aim of this study was to determine the neurophysiologic correlates of the amelioration of parkinsonism and the involuntary movements produced by the dopamine agonist apomorphine. Seventeen PD patients were given apomorphine (2-6 mg) before surgery. Neural activity was recorded for individual neurons and for populations of neurons before and after apomorphine. Both internal (GPi) and external (GPe) segments of the globus pallidus were sampled in patients undergoing pallidal surgery. The subthalamic nucleus (STN) was sampled in STN surgery patients. Results suggest that dopaminergic agents act by decreasing GPi and STN activity, and increasing GPe activity, and that drug-induced dyskinesias results from a large reduction in GPi firing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762141

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  29 in total

1.  Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.

Authors:  Xingxing Jin; Kerstin Schwabe; Joachim K Krauss; Mesbah Alam
Journal:  Exp Brain Res       Date:  2016-01-02       Impact factor: 1.972

2.  The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease.

Authors:  Sarah Lemieux; Mehrdad Ghassemi; Mandar Jog; Roderick Edwards; Christian Duval
Journal:  Exp Brain Res       Date:  2006-08-30       Impact factor: 1.972

3.  Network modulation in the treatment of Parkinson's disease.

Authors:  Kotaro Asanuma; Chengke Tang; Yilong Ma; Vijay Dhawan; Paul Mattis; Christine Edwards; Michael G Kaplitt; Andrew Feigin; David Eidelberg
Journal:  Brain       Date:  2006-07-14       Impact factor: 13.501

Review 4.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

5.  Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease.

Authors:  Jian Wang; YiLong Ma; ZheMin Huang; BoMin Sun; YiHui Guan; ChuanTao Zuo
Journal:  J Neurol       Date:  2009-08-07       Impact factor: 4.849

6.  The subthalamic nucleus in primary dystonia: single-unit discharge characteristics.

Authors:  Lauren E Schrock; Jill L Ostrem; Robert S Turner; Shoichi A Shimamoto; Philip A Starr
Journal:  J Neurophysiol       Date:  2009-10-21       Impact factor: 2.714

Review 7.  Selective GABA release as a mechanistic basis of high-frequency stimulation used for the treatment of neuropsychiatric diseases.

Authors:  Thomas J Feuerstein; Miriam Kammerer; Carl Hermann Lücking; Andreas Moser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

8.  Nicotinic receptor subtype-selective circuit patterns in the subthalamic nucleus.

Authors:  Cheng Xiao; Julie M Miwa; Brandon J Henderson; Ying Wang; Purnima Deshpande; Sheri L McKinney; Henry A Lester
Journal:  J Neurosci       Date:  2015-03-04       Impact factor: 6.167

9.  A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.

Authors:  Allison E Girasole; Matthew Y Lum; Diane Nathaniel; Chloe J Bair-Marshall; Casey J Guenthner; Liqun Luo; Anatol C Kreitzer; Alexandra B Nelson
Journal:  Neuron       Date:  2018-02-01       Impact factor: 17.173

Review 10.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.